Product Name :
Givinostat hydrochloride monohydrate
Description:
Givinostat hydrochloride monohydrate (ITF-2357 hydrochloride monohydrate) is a HDAC inhibitor with an IC50 of 198 and 157 nM for HDAC1 and HDAC3, respectively.
CAS:
732302-99-7
Molecular Weight:
475.97
Formula:
C24H30ClN3O5
Chemical Name:
{6-[(diethylamino)methyl]naphthalen-2-yl}methyl N-[4-(hydroxycarbamoyl)phenyl]carbamate hydrate hydrochloride
Smiles :
O.Cl.CCN(CC1=CC2=CC=C(COC(=O)NC3C=CC(=CC=3)C(=O)NO)C=C2C=C1)CC
InChiKey:
FKGKZBBDJSKCIS-UHFFFAOYSA-N
InChi :
InChI=1S/C24H27N3O4.ClH.H2O/c1-3-27(4-2)15-17-5-7-21-14-18(6-8-20(21)13-17)16-31-24(29)25-22-11-9-19(10-12-22)23(28)26-30;;/h5-14,30H,3-4,15-16H2,1-2H3,(H,25,29)(H,26,28);1H;1H2
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Givinostat hydrochloride monohydrate (ITF-2357 hydrochloride monohydrate) is a HDAC inhibitor with an IC50 of 198 and 157 nM for HDAC1 and HDAC3, respectively.{{Revefenacin} web|{Revefenacin} Neuronal Signaling|{Revefenacin} Purity & Documentation|{Revefenacin} In Vitro|{Revefenacin} custom synthesis|{Revefenacin} Epigenetic Reader Domain} |Product information|CAS Number: 732302-99-7|Molecular Weight: 475.{{GLP-1 receptor agonist 2} MedChemExpress|{GLP-1 receptor agonist 2} GPCR/G Protein|{GLP-1 receptor agonist 2} Protocol|{GLP-1 receptor agonist 2} Formula|{GLP-1 receptor agonist 2} custom synthesis|{GLP-1 receptor agonist 2} Autophagy} 97|Formula: C24H30ClN3O5|Chemical Name: {6-[(diethylamino)methyl]naphthalen-2-yl}methyl N-[4-(hydroxycarbamoyl)phenyl]carbamate hydrate hydrochloride|Smiles: O.Cl.CCN(CC1=CC2=CC=C(COC(=O)NC3C=CC(=CC=3)C(=O)NO)C=C2C=C1)CC|InChiKey: FKGKZBBDJSKCIS-UHFFFAOYSA-N|InChi: InChI=1S/C24H27N3O4.ClH.H2O/c1-3-27(4-2)15-17-5-7-21-14-18(6-8-20(21)13-17)16-31-24(29)25-22-11-9-19(10-12-22)23(28)26-30;;/h5-14,30H,3-4,15-16H2,1-2H3,(H,25,29)(H,26,28);1H;1H2|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : ≥ 100 mg/mL (210.10 mM).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.PMID:24189672 |Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Givinostat (ITF2357) suppresses total LPS-induced IL-1β production robustly compared with the reduction by ITF3056. At 25, 50, and 100 nM, Givinostat reduced IL-1β secretion more than 70%. Givinostat (ITF2357) suppresses the production of IL-6 in PBMCs stimulated with TLR agonists as well as the combination of IL-12 plus IL-18. IL-6 secretion decreases to 50% at 50 nM Givinostat (ITF2357), but at 100 and 200 nM, there is no reduction. As shown by the CCK-8 assay, Givinostat (ITF2357) inhibits JS-1 cell proliferation in a concentration-dependent manner. Treatment with Givinostat (ITF2357) ≥500 nM is associated with significant inhibition of JS-1 cell proliferation (PIn Vivo:|Givinostat (ITF2357) at 10 mg/kg is used as a positive control and, as expected, reduced serum TNFα by 60%. Strikingly, pretreatment of ITF3056 starting at 0.1 mg/kg significantly reduces the circulating TNFα by nearly 90%. To achieve a significant increase in serum IL-1β production, a higher dose of LPS is injected (10 mg/kg), and blood is collected after 4 h. Similarly, when pretreated with lower doses of Givinostat (ITF2357) (1 or 5 mg/kg), there is a 22% reduction for 1 mg/kg and 40% for 5 mg/kg.|Products are for research use only. Not for human use.|
